Scalper1 News
Spinal-product specialist NuVasive (NUVA) got an upgrade and two price-target increases Wednesday after its Q2 earnings beat estimates late Tuesday. The stock hit a seven-year high in early trading. NuVasive’s profit rose 11% over the year-earlier quarter to 31 cents a share, beating analysts’ consensus by 6 cents, according to Thomson Reuters. Sales rose 6% to $202.9 million, about $2 million above estimates. NuVasive added 7 cents to its Scalper1 News
Scalper1 News